Abstract
Protein misfolding causes a phenotype of disorders that is modulated by the action of multi-complexes formed by molecular chaperones and the proteasome machine. Hsp90 is a molecular chaperone involved in maintaining folding, stability and function of many proteins involved in apoptosis, signal-transduction pathways and cell-cycle regulation. Many of these proteins are usually deregulated in cancers and by keeping them active Hsp90 helps the stabilization of tumorogenic cells. Therefore, inhibition of Hsp90 will result in degradation of its client proteins via the proteasome followed by a down regulation of several properties of the malignant phenotype. As a consequence, Hsp90 has been considered to be an appealing target for cancer therapeutics because its inhibition can affect multiple oncogenic pathways simultaneously. Major efforts have generated Hsp90 inhibitors that passed Phase I clinical trials and have entered Phase II trials. Furthermore, other compounds are in development to improve efficacy as antitumor agents. In conclusion, the development of Hsp90 inhibitors is considered to be a good example of medicinal chemistry. Specific important aspects of Hsp90 structure and function, the role of the chaperone in cancer and the development of Hsp90 inhibitors that causes growth arrest and apoptosis in cancer cells are discussed.
Keywords: medicinal chemistry, antitumor drugs, geldanamycin, cancer therapeutics, molecular chaperone, Hsp90 inhibitors
Current Chemical Biology
Title: Human 90 kDa Heat Shock Protein Hsp90 as a Target for Cancer Therapeutics
Volume: 3 Issue: 1
Author(s): Lisandra M. Gava and Carlos H.I. Ramos
Affiliation:
Keywords: medicinal chemistry, antitumor drugs, geldanamycin, cancer therapeutics, molecular chaperone, Hsp90 inhibitors
Abstract: Protein misfolding causes a phenotype of disorders that is modulated by the action of multi-complexes formed by molecular chaperones and the proteasome machine. Hsp90 is a molecular chaperone involved in maintaining folding, stability and function of many proteins involved in apoptosis, signal-transduction pathways and cell-cycle regulation. Many of these proteins are usually deregulated in cancers and by keeping them active Hsp90 helps the stabilization of tumorogenic cells. Therefore, inhibition of Hsp90 will result in degradation of its client proteins via the proteasome followed by a down regulation of several properties of the malignant phenotype. As a consequence, Hsp90 has been considered to be an appealing target for cancer therapeutics because its inhibition can affect multiple oncogenic pathways simultaneously. Major efforts have generated Hsp90 inhibitors that passed Phase I clinical trials and have entered Phase II trials. Furthermore, other compounds are in development to improve efficacy as antitumor agents. In conclusion, the development of Hsp90 inhibitors is considered to be a good example of medicinal chemistry. Specific important aspects of Hsp90 structure and function, the role of the chaperone in cancer and the development of Hsp90 inhibitors that causes growth arrest and apoptosis in cancer cells are discussed.
Export Options
About this article
Cite this article as:
Gava M. Lisandra and Ramos H.I. Carlos, Human 90 kDa Heat Shock Protein Hsp90 as a Target for Cancer Therapeutics, Current Chemical Biology 2009; 3 (1) . https://dx.doi.org/10.2174/2212796810903010010
DOI https://dx.doi.org/10.2174/2212796810903010010 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DNA and RNA Aptamers as Modulators of Protein Function
Medicinal Chemistry Transductional and Transcriptional Targeting of Adenovirus for Clinical Applications
Current Gene Therapy Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment
Current Cancer Therapy Reviews Cancer Stem Cells: The Emerging Challenge of Drug Targeting
Current Medicinal Chemistry Biomarkers and Future Targets for Development in Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry Changes of Gene Expression in the Developing Brain by Acute Ethanol Exposure
Current Psychopharmacology CD93 and Related Family Members: Their Role in Innate Immunity
Current Drug Targets Recent Advances in Combretastatin A-4 Inspired Inhibitors of Tubulin Polymerization: An Update
Current Medicinal Chemistry The Novel VEGF<sub>121</sub>-VEGF<sub>165</sub> Fusion Attenuates Angiogenesis and Drug Resistance via Targeting VEGFR2-HIF-1α-VEGF<sub>165</sub>/Lon Signaling Through PI3K-AKT-mTOR Pathway
Current Cancer Drug Targets Personalized Nanoparticles for Cancer Therapy: A Call for Greater Precision
Anti-Cancer Agents in Medicinal Chemistry Liposome-Nanogel Structures for Future Pharmaceutical Applications: An Updated Review
Current Pharmaceutical Design Selenosemicarbazone Metal Complexes as Potential Metal-based Drugs
Current Medicinal Chemistry Radionuclide Based Imaging of Prostate Cancer
Current Topics in Medicinal Chemistry A Review on Imaging Techniques and Artificial Intelligence Models for Osteoporosis Prediction
Current Medical Imaging Genomic Organization and Control of the Grb7 Gene Family
Current Genomics Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry A Review of Ewing Sarcoma Treatment: Is it Still a Subject of Debate?
Reviews on Recent Clinical Trials State-of-the-Art Lentiviral Vectors for Research Use: Risk Assessment and Biosafety Recommendations
Current Gene Therapy Pregnancy, Programming and Preeclampsia: Gap Junctions at the Nexus of Pregnancy-induced Adaptation of Endothelial Function and Endothelial Adaptive Failure in PE
Current Vascular Pharmacology Reversing Agents for ATP-Binding Cassette (ABC) Transporters: Application in Modulating Multidrug Resistance (MDR)
Current Medicinal Chemistry - Anti-Cancer Agents